Showing 5321-5330 of 5621 results for "".
- CEI Vision Partners Adds Virginia Eye Consultants as Fifth Partnerhttps://modernod.com/news/cei-vision-partners-adds-virginia-eye-consultants-as-fifth-partner/2476310/CEI Vision Partners (CVP), a portfolio company of Revelstoke Capital Partners LLC , a Denver-based private equity firm, has completed a partnership with Virginia Eye Consultants (VEC) , a premier multi-specialty ophthalmology group comprised of 17 providers that service the Norfolk, Virginia Beac
- EU-5 Ophthalmic Market Will Top $10 Billion in 2023https://modernod.com/news/eu-5-ophthalmic-market-will-top-10-billion-in-2023/2476311/Market Scope expects growing demand for retinal pharmaceuticals to help manufacturers’ ophthalmic revenues top $10 billion in 2023 in the five largest economies of the European Union. The ophthalmic markets in France, Germany, Italy, Spain, and the UK––the five countries that made up
- Regeneron Q4 Earnings & Sales Beat on Strong Eylea Saleshttps://modernod.com/news/regeneron-q4-earnings-sales-beat-on-strong-eylea-sales/2476314/Regeneron Pharmaceuticals delivered impressive results in the fourth quarter of 2018 wherein both earnings and sales beat estimates, according to a Nasdaq report. Shares ar
- Graybug Vision Appoints Frédéric Guerard as Chief Executive Officerhttps://modernod.com/news/graybug-vision-appoints-frederic-guerard-as-chief-executive-officer/2476318/Graybug Vision announced that the board of directors has appointed Frédéric Guerard as Chief Executive Officer. Mr. Guerard’s career in the pharmaceutical industry spans over 20 years and includes multiple leadership, strategic, and commercial roles. He joins from Novartis, where he was pr
- Galimedix Therapeutics Presents Data for Investigational Eyedrops Containing GAL-101https://modernod.com/news/galimedix-therapeutics-presents-data-for-investigational-eyedrops-containing-gal-101/2476320/Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, presented an overview of data disclosed to date on its novel, first-in-class, investigational compound GAL-101, which in animal models caused sustained prevention of misfolded amyloid beta mol
- Harrow Health Announces $11 Million Series A Financing for Melt Pharmaceuticals Subsidiaryhttps://modernod.com/news/harrow-health-announces-11-million-series-a-financing-for-melt-pharmaceuticals-subsidiary/2476323/Melt Pharmaceuticals, an affiliated company of Harrow Health, announced it has entered into definitive stock purchase agreements with accredited and institutional investors to raise proceeds of approximately $11 million in a private placement sale of its Series A preferred stock at $5 per share.
- Bausch + Lomb Launches Sightmatters.com to Help People Living With AMDhttps://modernod.com/news/bausch-lomb-launches-sightmatters-com-to-help-people-living-with-amd/2476325/Bausch + Lomb announced the launch of SightMatters.com, a new educational online resource for people living with age-related macular degeneration (AMD). Bausch + Lomb launched the site to coincide with the start of AMD Awareness Month. The new online resource, which was specifically design
- CorneaGen to Acquire KeraLink Domestic Eye Bank Operationshttps://modernod.com/news/corneagen-to-acquire-keralink-domestic-eye-bank-operations/2476326/CorneaGen and KeraLink International, a provider of corneal transplantation services, supplies and grafts for transplant, have signed a final agreement for CorneaGen to acquire KeraLink’s domestic eye bank operations and related assets. Financial terms of the deal were not disclosed. <
- SECO International Names J. Max Ernst, OD, as 2020 Presidenthttps://modernod.com/news/seco-international-names-j-max-ernst-od-as-2020-president/2476329/SECO International, the world’s largest educational conference, has announced that J. Max Ernst, OD, will become the next SECO International President. Dr. Ernst will officially accept the honor during the House of Delegates meeting, held during SECO 2019, Saturday, February 23, from 3:15 pm-5 pm
- Johnson & Johnson Vision Announces Availability in Europe of Tecnis Eyhance IOLhttps://modernod.com/news/johnson-johnson-vision-announces-availability-in-europe-of-tecnis-eyhance-iol/2476332/Johnson & Johnson Vision announced the launch of its Tecnis Eyhance IOL in Europe. This next-generation monofocal IOL allows patients to experience high-quality vision at both intermediate and far distances. “With the availability of Tecnis Eyhance IOL in Europe, we are proud to deliv